As human recombinant erythropoietin (rhEPO) directly inhibits pulmonary fibrosis by binding to EPOR on alveolar and bronchial epithelial cells (24), it may promote the healing of these cells damaged by anticancer drugs via the induction of vascular endothelial precursor cells in the bone marrow, thereby indirectly inhibiting pulmonary fibrosis (25). Here, EPO is linked to pulmonary fibrosis.